Literature DB >> 16859831

Conantokins and variants derived from cone snail venom inhibit naloxone-induced withdrawal jumping in morphine-dependent mice.

Juanjuan Wei1, Mingxin Dong, Cai Xiao, Fengchao Jiang, Francis J Castellino, Mary Prorok, Qiuyun Dai.   

Abstract

The biochemical processes underlying opiate addiction are complex, but n-methyl-d-aspartate receptor (NMDAR) dysfunction appears to be one contributing factor. NMDAR antagonists, including MK-801 and memantine, have previously been shown to assuage symptoms stemming from opiate withdrawal. The conantokins are a small family of naturally occurring peptide toxins known to specifically antagonize the NMDAR. In the present study, the effects of wild-type and variant conantokins on the suppression of naloxone-induced jumping in morphine-dependent mice were evaluated. Our results demonstrate that NR2B-selective conantokins, viz., con-G, con-G[S(16)Y] and con-G[gamma(7)K], are potent inhibitors of naloxone-induced jumping at low doses (2-15 nmol/kg) compared with con-T, con-R[1-17], and small-molecule antagonists of the NMDAR, including the NR2B-selective agent, ifenprodil. We conclude that the NR2B-selective conantokins may find utility as neuropharmacological tools for probing NMDAR-related mechanisms of opiate dependence.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16859831     DOI: 10.1016/j.neulet.2006.06.040

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  11 in total

1.  Opposing action of conantokin-G on synaptically and extrasynaptically-activated NMDA receptors.

Authors:  Rashna Balsara; Neill Li; Danielle Weber-Adrian; Louxiu Huang; Francis J Castellino
Journal:  Neuropharmacology       Date:  2012-01-27       Impact factor: 5.250

Review 2.  Endogenous opiates and behavior: 2006.

Authors:  Richard J Bodnar
Journal:  Peptides       Date:  2007-09-11       Impact factor: 3.750

3.  Hydroxyproline-induced Helical Disruption in Conantokin Rl-B Affects Subunit-selective Antagonistic Activities toward Ion Channels of N-Methyl-d-aspartate Receptors.

Authors:  Shailaja Kunda; Yue Yuan; Rashna D Balsara; Jaroslav Zajicek; Francis J Castellino
Journal:  J Biol Chem       Date:  2015-06-05       Impact factor: 5.157

4.  Probing NMDA receptor GluN2A and GluN2B subunit expression and distribution in cortical neurons.

Authors:  Rashna D Balsara; Ashley N Ferreira; Deborah L Donahue; Francis J Castellino; Patrick L Sheets
Journal:  Neuropharmacology       Date:  2014-01-15       Impact factor: 5.250

5.  Specific determinants of conantokins that dictate their selectivity for the NR2B subunit of N-methyl-D-aspartate receptors.

Authors:  Z Sheng; M Prorok; F J Castellino
Journal:  Neuroscience       Date:  2010-08-03       Impact factor: 3.590

6.  Conantokins inhibit NMDAR-dependent calcium influx in developing rat hippocampal neurons in primary culture with resulting effects on CREB phosphorylation.

Authors:  Luoxiu Huang; Rashna D Balsara; Zhenyu Sheng; Francis J Castellino
Journal:  Mol Cell Neurosci       Date:  2010-06-21       Impact factor: 4.314

7.  IL-4 mediated by HSV vector suppresses morphine withdrawal response and decreases TNFα, NR2B, and pC/EBPβ in the periaqueductal gray in rats.

Authors:  H Yi; T Iida; S Liu; D Ikegami; Q Liu; A Iida; D A Lubarsky; S Hao
Journal:  Gene Ther       Date:  2017-03-16       Impact factor: 5.250

8.  Subtype-selective antagonism of N-methyl-D-aspartate receptor ion channels by synthetic conantokin peptides.

Authors:  Zhenyu Sheng; Qiuyun Dai; Mary Prorok; Francis J Castellino
Journal:  Neuropharmacology       Date:  2007-05-10       Impact factor: 5.250

9.  Pharmacodynamics of memantine: an update.

Authors:  G Rammes; W Danysz; C G Parsons
Journal:  Curr Neuropharmacol       Date:  2008-03       Impact factor: 7.363

10.  Antagonist properties of Conus parius peptides on N-methyl-D-aspartate receptors and their effects on CREB signaling.

Authors:  Shailaja Kunda; John Cheriyan; Michael Hur; Rashna D Balsara; Francis J Castellino
Journal:  PLoS One       Date:  2013-11-18       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.